114 related articles for article (PubMed ID: 20000847)
1. Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells.
van Rijt SH; Mukherjee A; Pizarro AM; Sadler PJ
J Med Chem; 2010 Jan; 53(2):840-9. PubMed ID: 20000847
[TBL] [Abstract][Full Text] [Related]
2. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
3. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
4. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
5. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
6. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
7. DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media.
Kostrhunova H; Florian J; Novakova O; Peacock AF; Sadler PJ; Brabec V
J Med Chem; 2008 Jun; 51(12):3635-43. PubMed ID: 18494458
[TBL] [Abstract][Full Text] [Related]
8. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
9. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
10. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
11. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
[TBL] [Abstract][Full Text] [Related]
12. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
13. Organometallic osmium arene complexes with potent cancer cell cytotoxicity.
Fu Y; Habtemariam A; Pizarro AM; van Rijt SH; Healey DJ; Cooper PA; Shnyder SD; Clarkson GJ; Sadler PJ
J Med Chem; 2010 Nov; 53(22):8192-6. PubMed ID: 20977192
[TBL] [Abstract][Full Text] [Related]
14. Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells.
van Rijt SH; Romero-Canelón I; Fu Y; Shnyder SD; Sadler PJ
Metallomics; 2014 May; 6(5):1014-22. PubMed ID: 24668459
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of osmium metalla-rectangles.
Barry NP; Edafe F; Dyson PJ; Therrien B
Dalton Trans; 2010 Mar; 39(11):2816-20. PubMed ID: 20200707
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Organometallic Osmium(II)-p-cymene Complexes.
Păunescu E; Nowak-Sliwinska P; Clavel CM; Scopelliti R; Griffioen AW; Dyson PJ
ChemMedChem; 2015 Sep; 10(9):1539-47. PubMed ID: 26190176
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]